0001177648-20-000037.txt : 20201120
0001177648-20-000037.hdr.sgml : 20201120
20201120202548
ACCESSION NUMBER: 0001177648-20-000037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201120
FILED AS OF DATE: 20201120
DATE AS OF CHANGE: 20201120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MELLETT PAUL J
CENTRAL INDEX KEY: 0001185034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 201334084
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-11-20
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001185034
MELLETT PAUL J
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Treasurer and CFO
Common Stock
2020-11-20
4
A
0
7600
0.0
A
53904
D
Stock Option (right to buy)
43.57
2020-11-20
4
A
0
30800
0.0
A
2030-11-20
Common Stock
30800
30800
D
Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 20, 2020). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.
Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
/s/ Nathaniel S. Gardiner as attorney-in-fact
2020-11-20